期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

9-硝基喜树碱酯类衍生物的合成和结构表征 被引量：1

Synthesis and Characterization of 9-nitrocamptothecin C-10 Esters
下载PDF
导出
摘要 以10-羟基喜树碱为原料,经硝化反应制备中间体9-硝基-10-羟基喜树碱,再经亲核取代反应合成新的9-硝基喜树碱酯类衍生物。对反应路线的选择及反应中间体和终产物的结构进行了详细解析,化合物的结构经1HNMR、13C NMR、IR和MS(ESI)表征。结果表明:此合成路线反应条件温和,产物总转化率达到90.2%。 A study was conducted to synthesize 9-nitrocamptothecin C-10 esters in order to find out a new type of camptothecin prodrug with low toxicity.10-hydroxycamptothecin was used as raw material to prepare 9-nitro-10-hydroxycamptothecin by nitration,and then two new 9-nitrocamptothecin ester derivatives were synthesized by nucleophile substitution with ethyl bromoacetate.The selection of synthetic route and the structure of the final products were discussed in detail.The structure of each compound was characterized by 1H NMR,13C NMR,IR and MS（ESI）.Results indicate that the selected synthetic route is easy to perform under mild conditions,and the maximum yield of the final products reached 90.2%.
作者 牟璠松 罗猛 付玉杰 张谡 祖元刚
机构地区 森林植物生态学教育部重点实验室(东北林业大学)
出处 《东北林业大学学报》 CAS CSCD 北大核心 2010年第1期74-75,83,共3页 Journal of Northeast Forestry University
基金 国家自然科学基金项目(30770231) 黑龙江省杰出青年科学基金项目(JC200704) 黑龙江省自然科学基金项目(C200933) 东北林业大学青年科研基金项目(07021)
关键词 9-硝基喜树碱 酯类衍生物 亲核取代反应 9-nitrocamptothecin Ester derivatives Nucleophile substitution reactions
分类号 R914.5 [医药卫生—药物化学]
  • 相关文献

参考文献12

  • 1Wall M E,Wani M C,Cook C E,et al.Plant antitumor agents.I.The isolation and structure of camptothecin,a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate[J].J Am Chem Soc,1966,88(16):3888-3890.
  • 2Hsiang Y H,Hertzberg R,Hecht S,et al.Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerase I[J].J Biol Chem,1985,260(27):14873-14878.
  • 3Redinbo M R,Stewart L,Kuhn P,et al.Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA[J].Science,1998,279:1504-1513.
  • 4Sawada S,Matsuoka S,Nokata K,et al.Synthesis and antitumor activity of 20(S) camptothecin derivatives:A ring modified and 7,10 disubstitute camptothecins[J].Chem Pharm Bull,1991,39(12):3183-3188.
  • 5Sugimori M,Ejima A,Ohsuki S,et al.Antitumor agents.VI.Synthesis and antitumor activity of ring A,ring B,and ring C modified derivatives of camptothecin[J].Heterocycles,1994,38(1):81-94.
  • 6Zu Yuangang,Li Qingyong,Fu Yujie,et al.Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin[J].Bioorg Med Chem Lett,2004,14(15):4023-4026.
  • 7牟松,罗猛,祖元刚,李庆勇.喜树碱及其衍生物结构修饰及构效关系的研究[J].中国药学杂志,2006,41(11):804-806. 被引量：8
  • 8Pantazis P,Han Z Y,Chatterjee D,et al.9 Nitrocamptothecin[J].Drug Fut,1999,24(12):1311-1323.
  • 9Cao Zhisong,Harris N,Kozielski A,et al.Alkyl esters of camptothecin and 9 nitrocamptothecin:synthesis,in vitro pharmacokinetics,toxicity,and antitumor activity[J].J Med Chem,1998,41(1):31-37.
  • 10He Xungui,Lu Wei,Jiang Xiqun,et al.Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10 hydroxycamptothecins[J].Bioorg Med Chem,2004,12(15):4003-4008.

二级参考文献32

  • 1LERCHEN H G,BAUMGARTEN J,BRUCH K,et al.Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents[J].J Med Chem,2001,44(24):4186-4195.
  • 2BAILLY C.Homocamptothecins:potent topoisomerase I inhibitors and promising anticancer drugs[J].Crit Rev Oncol Hematol,2003,45(1):91-108.
  • 3ZUNINO F,PRATESI G.Camptothecins in clinical development[J].Expert Opin Investig Drugs,2004,13(3):269-284.
  • 4GARC A-CARBONERO R,SUPKO J G.Current perspectives on the clinical experience,pharmacology,and continued development of the camptothecins[J].Clin Cancer Res,2002,8(3):641-661.
  • 5SUBRAHMANYAM D,SARMA V M,VENKATESWARLU A,et al.Novel C-ring analogues of 20(S)-camptothecin.Part 3:synthesis and their irn vitro cytotoxicity of A-,B-and C-ring analogues[J].Bioorg Med Chem Lett,2000,10(4):369-371.
  • 6SUBRAHMANYAM D,VENKATESWARLU A,RAO K V,et al.Novel C-ring analogues of 20(S)-camptothecin.Part 2:synthesis and in vitro cytotoxicity of 5-C-substituted 20 (S)-camptothecin analogues[J].Bioorg Med Chem Lett,1999,9(12):1633-1638.
  • 7SUGIMORI M,EJIMA A,OHSUKI S,et al.Antitumor agents.Ⅵ.synthesis and antitumor activity of ring A-,ring B-,and ring C-modified derivatives of camptothecin[J].Heterocycles,1994,38(1):81-94.
  • 8HERTZBERG R P,CARANFA M J,HOLDEN K G,et al.Modification of the hydroxylactone ring of camptothecin:inhibition of mammalian topoisomerase I and biological activity[J].J Med Chem,1989,32(3):715-720.
  • 9NICHOLAS A W,WANI M W,MANIKUMAR G,et al.Plant antitumor agents.29.Synthesis and biological activity of ring D and ring E modified analogs of camptothecin[J].J Med Chem,1990,33 (3):972-978.
  • 10YANG S C,ZHU J B.Preparation and characterization of camptothecin solid lipid nanoparticles[J].Drug Dev Ind Pharm,2002,28(1):265-274.

共引文献9

同被引文献5

引证文献1

二级引证文献2

东北林业大学学报
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部